What we do Cipla Limited is a leading Indian pharmaceutical company developing, manufacturing, and marketing branded and generic medicines across diverse therapeutic segments globally. |
Founded in 1,935 |
Market share Strong presence in India, South Africa, North America, and emerging markets, with leading positions in respiratory and antiretroviral therapies. |
Problem solved Provides affordable and accessible medicines for chronic, infectious, and critical diseases to improve patient health worldwide. |
Top clients or who we serve Serves hospitals, pharmacies, healthcare providers and patients globally; operates in B2B and B2C pharmaceutical markets. |
Key management Kamil M. Hamied - Non-Executive Director; Rajeev Shukla - CEO and Managing Director (noted pharma industry experts). |
Our journey and innovations Founded in 1935; pioneered indigenous penicillin, introduced India's first transparent Rotahaler dry powder inhaler, launched biosimilars, and developed novel respiratory therapies. |
Where we operate India, United States, South Africa, Europe, Asia, Africa, and Latin America with 49 subsidiaries and multiple manufacturing facilities worldwide. |
Top products or what we offer Wide portfolio including respiratory, antiretroviral, oncology, cardiology, and CNS drugs; key brands: Foracort, Indaflo, Cipladine, Hepcvir-L. |
Top brands Foracort (top respiratory brand in India), Nicotex (#1 in nicotine replacement India), Indaflo (respiratory), Hepcvir-L (hepatitis C therapy), Cipla's Albuterol inhaler (US market leader). |
Raw materials needed Active Pharmaceutical Ingredients (APIs), chemical intermediates, biotech materials for biosimilars, natural products for formulations. |
Raw materials supplier Sourced from global and local suppliers meeting stringent quality and regulatory norms; strategic partnerships ensure supply continuity. |
Recurring vs cyclical contribution Majority revenue from recurring sales of pharmaceuticals; some cyclical elements due to regulatory approvals and patent expiries. |
Our industry position Among top Indian pharma firms with significant global footprint; leader in respiratory and anti-retroviral markets; robust R&D pipeline. |
Financial highlights FY2024-25 consolidated revenue Rs 27,547 crore, profit after tax Rs 5,273 crore; strong double-digit growth in India and other key markets. |
Geographical revenue split India 42%, United States 29%, Africa 14%, Rest of World 15% |
Order book Not explicitly disclosed; steady growth expected driven by new product launches and strategic acquisitions. |
Whats driving growth Innovation in respiratory and specialty therapies, expanding geographic reach, strategic acquisitions, digital health initiatives, and deepening patient engagement. |
Our future plans Expand specialty product portfolio, enhance manufacturing capacity, launch new respiratory devices, and increase presence in biotech biosimilars. |
Our green promise Committed to 30% carbon reduction by 2030, water neutrality, zero waste to landfill, and responsible sourcing adhering to ESG standards. |
Our people and values Diverse workforce focused on innovation, patient-centricity, sustainability, and inclusive workplace culture. |
Key challenges ahead Regulatory complexities, pricing pressures, competitive generics market, supply chain disruptions, and sustaining innovation pipeline. |
Interesting facts Cipla pioneered anti-retroviral therapy access in India, launched world's first transparent Rotahaler, and offers India’s first pneumotach portable spirometer. |
Risks and strategy Risks include regulatory delays and IP challenges; strategy focuses on robust R&D, diversified markets, compliance excellence, and strategic partnerships. |
